Loading...
  • pancreatic cancer
  • As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. (tmcnet.com)
  • Magnetically responsive microbubbles (MagMBs), consisting of an oxygen gas core and a phospholipid coating functionalised with Rose Bengal (RB) and/or 5-fluorouracil (5-FU), were assessed as a delivery vehicle for the targeted treatment of pancreatic cancer using combined antimetabolite and sonodynamic therapy (SDT). (anglia.ac.uk)
  • These results suggest MagMBs have considerable potential as a platform to enable the targeted delivery of combined sonodynamic / antimetabolite therapy in pancreatic cancer. (anglia.ac.uk)
  • A statistically significant reduction in cell viabilitywas observed when three different pancreatic cancer cell lines (BxPc-3, MIA PaCa-2 and PANC-1),cultured in an anaerobic cabinet, were treated with both SDT and antimetabolite therapy compared toeither therapy alone. (ulster.ac.uk)
  • These results illustrate not only the potential ofcombined SDT/antimetabolite therapy as a stand alone treatment option in pancreatic cancer, but alsothe capability of O2-loaded MBs to deliver O2 to the tumour microenvironment in order to enhance theefficacy of therapies that depend on O2 to mediate their therapeutic effect. (ulster.ac.uk)
  • Gene Expression
  • It remains to be investigated whether any differences among antimetabolite agents can be captured in gene expression signatures of response and whether such gene expression signatures can add to our power of distinguishing subtypes with heterogeneous therapeutic outcome. (biomedcentral.com)
  • drug
  • The purpose of this study was to examine the role of Fas-mediated apoptosis in mediating cell death in response to the antimetabolite drugs 5-FU, RTX, and MTA and to assess the effect of TS induction and p53 status on drug-induced activation of this pathway. (aacrjournals.org)
  • This drug panel included a number of antimetabolite chemotherapies together with a number of other agents grouped as "cytotoxic drugs. (biomedcentral.com)
  • drugs
  • Antimetabolite drugs are commonly used to treat leukemia, cancers of the breast, ovary, and the gastrointestinal tract, as well as other types of cancers. (wikipedia.org)
  • In the Anatomical Therapeutic Chemical Classification System antimetabolite cancer drugs are classified under L01B. (wikipedia.org)
  • We provide evidence against the common notion about non-specific cytotoxic functions of antimetabolite drugs. (biomedcentral.com)
  • Furthermore, the use of MBsto facilitate delivery of O2 as well as the sensitiser/antimetabolite, combined with the possibility toactivate the sensitiser using externally applied ultrasound, provides a more targeted approach withimproved efficacy and reduced side effects when compared with conventional systemic administrationof antimetabolite drugs alone. (ulster.ac.uk)
  • replication
  • Antimetabolites generally impair DNA replication machinery, either by incorporation of chemically altered nucleotides or by depleting the supply of deoxynucleotides needed for DNA replication and cell proliferation. (wikipedia.org)
  • Because of this mode of action, most antimetabolites have high cell cycle specificity and can target arrest of cancer cell DNA replication. (wikipedia.org)
  • genetic
  • A general overview of the genetic organization and biosynthetic and regulatory functions of these genetic traits of the antimetabolite toxins will be given in the present work. (mdpi.com)
  • malignant
  • Generally, the most sensitive cells to the antimetabolite effect of trimetrexate are those cells which are most actively proliferating such as malignant cells, dermal epithelium, buccal and intestinal mucosa, bone marrow, fetal cells, and cells of the urinary bladder. (pharmacycode.com)
  • normal
  • When the cancer cell uses an antimetabolite instead of the natural substances, it can't produce normal DNA or RNA and the cell dies. (lls.org)
  • Study
  • This study comprehensively evaluated thousands of molecular features in their ability to act as predictive markers of sensitivity and found the TP53 mutational status as the most dominant marker for antimetabolite agents such as 5-FU and Gemcitabine. (biomedcentral.com)